I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009). I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics, 86(1), 97-100.

Type

Journal article

Intellectual base

Primary research

Year

2009

Volume

86

Issue

1

Pages

97-100

DOI

10.1038/clpt.2009.68

DOI registrant

Wiley

Link

https://doi.org/10.1038/clpt.2009.68

Cited from

statistics_experimental_design

Cited by

1 citation across 1 artifact.

Each citation links to the sentence it supports in the citing article.

Primes

• Bayesian Updating
  • The I-SPY 2 trial for neoadjuvant breast cancer treatment, initiated in 2010 by UCSF investigators in collaboration with the FDA and industry partners, is a landmark application of Bayesian adaptive design in oncology

    This sourceSUPPORTS marker 011 (re-sourced from jeffreys-1961, which is about objective priors and does not concern I-SPY 2).

Verification

Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.

Does it back the claim? Not recorded. The single citation of this work carries no recorded support check.

Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.

See how references were verified.

Registry ID ref:08ca7097e2e5 · see in the full table